---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-013481"
form_type: "8-K"
ticker: "PLX"
cik: "0001006281"
company_name: "Protalix BioTherapeutics, Inc."
filed_at: "2023-08-07T23:59:59+00:00"
generated_at: "2026-06-12T03:37:36.747101+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Protalix reports Q2 net income of $19.3M on Elfabrio sales and $20M milestone

## Summary
- Revenue from goods $15.1M (+344% YoY) driven by Elfabrio sales to Chiesi after FDA/EMA approvals.
- License & R&D revenue $20.0M (+270% YoY) from $20M regulatory milestone payment from Chiesi.
- Net income $19.3M ($0.29 basic EPS) vs net loss of $5.3M in Q2 2022; cash $48.2M.
- Elfabrio received US FDA (May 10) and EU (May 5) approval for adult Fabry disease; launched in US by Chiesi.
- PRX-115 phase I trial for severe gout ongoing; 16 patients dosed to date.

## SEC filing metadata
- accession: 0001558370-23-013481
- form_type: 8-K
- ticker: PLX
- cik: 0001006281
- company_name: Protalix BioTherapeutics, Inc.
- filed_at: 2023-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1006281/000155837023013481/0001558370-23-013481-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1006281/000155837023013481/plx-20230807x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-013481
- JSON: https://secwatch.observer/filing/0001558370-23-013481.json
- Plain text: https://secwatch.observer/filing/0001558370-23-013481.txt

## Key facts
- Earnings Releases
  Protalix BioTherapeutics, Inc. reported financial results for three months ended June 30, 2023.
  - Period: three months ended June 30, 2023
  - Result: reported results
  source text: On August 7, 2023, Protalix BioTherapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2023 and provided a business update on recent regulatory, clinical and corporate developments.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1006281/000155837023013481/0001558370-23-013481-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.